Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Oxford Immunotec Global PLC was a global, commercial-stage diagnostics company focused on developing and commercializing proprietary T-cell measurement technology for the ELISPOT platform. Its flagship product, the T-SPOT®.TB test, is a globally recognized ELISPOT-based assay for diagnosing latent tuberculosis infection. Founded in 2002 as a spin-out from the University of Oxford, the company dedicated itself to advancing immunology-based diagnostics. In March 2021, Oxford Immunotec was acquired by PerkinElmer, Inc. Subsequently, in May 2023, PerkinElmer's life sciences and diagnostics businesses, including the operations and technologies of Oxford Immunotec, were divested and rebranded as Revvity, Inc. Oxford Immunotec's legacy of innovation in T-cell diagnostics continues within Revvity, aiming to improve patient care through advanced diagnostic tools that assess immune function.
Serves as a central hub for research and development, manufacturing, and administrative operations for Oxford Immunotec's diagnostic products, particularly the T-SPOT.TB test, now under Revvity's portfolio.
Located within Milton Park, one of Europe's largest science, technology, and business communities, offering modern laboratory and office facilities designed for biotech innovation and collaboration.
Historically fostered a collaborative and innovative environment focused on scientific excellence, quality, and a commitment to improving global health. As part of Revvity, it contributes to a broader culture dedicated to impacting human health through scientific discovery, advanced diagnostics, and a passion for results.
The Abingdon site remains crucial for the global supply, quality control, and ongoing development of the T-SPOT.TB test. It represents a key center of expertise in T-cell diagnostics and ELISPOT technology within Revvity.
Oxford Immunotec's technologies, now part of Revvity, have a significant global footprint. Revvity supports the worldwide distribution and use of the T-SPOT.TB test and other diagnostic solutions through direct operations, dedicated teams, and strategic partnerships across North America, Europe, Asia, and other key international markets. Global functions managed by Revvity include sales and marketing, customer and technical support, manufacturing and supply chain, research and development, and regulatory affairs to ensure these diagnostic solutions meet diverse international standards and effectively reach patients and healthcare providers globally.
94C Innovation Drive, Milton Park
Abingdon
Oxfordshire
United Kingdom
Address: 500 Nickerson Road, Suite 200, Marlborough, MA 01752, USA (historical address, operations now integrated with Revvity's US sites)
To facilitate access to and support for Oxford Immunotec's diagnostic products in the United States and Canada. This role continues under Revvity to serve healthcare providers, public health organizations, and patients in the region.
Address: Revvity Singapore Pte. Ltd. (Specific Oxford Immunotec address integrated)
To expand access to advanced TB diagnostics and support healthcare systems in the APAC region in managing tuberculosis and other immune-related conditions.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, OXFORD IMMUNOTEC GLOBAL PLC' leadership includes:
OXFORD IMMUNOTEC GLOBAL PLC has been backed by several prominent investors over the years, including:
Following its acquisition by PerkinElmer in 2021 and the subsequent formation of Revvity in 2023, executive roles specific to the former 'Oxford Immunotec Global PLC' entity have been integrated into the broader Revvity leadership structure. Distinct executive news for 'Oxford Immunotec' as a standalone brand is generally reflected in appointments or changes within Revvity's diagnostics or relevant regional leadership teams. No specific 'Oxford Immunotec Global PLC' branded executive hires or exits have been announced in the last 12 months under that distinct name.
Discover the tools OXFORD IMMUNOTEC GLOBAL PLC uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Personnel associated with Oxford Immunotec's products and operations, now part of Revvity, typically use Revvity's corporate email format. Common formats include [first].[last]@revvity.com or [first_initial][last]@revvity.com. Historically, Oxford Immunotec likely used similar structures with its own domain (e.g., @oxfordimmunotec.com).
[first].[last]@revvity.com or [first_initial][last]@revvity.com
Format
john.doe@revvity.com or jdoe@revvity.com
Example
80%
Success rate
Revvity Official Website • May 9, 2023
Revvity Inc. officially launched, following the divestiture of PerkinElmer's applied, food and enterprise services businesses. Revvity combines the former life sciences and diagnostics businesses, including the advanced T-cell diagnostic technologies developed by Oxford Immunotec, to focus on improving human health through scientific innovation and a mission to expand the boundaries of human potential through science....more
PerkinElmer (via Business Wire) • March 16, 2021
PerkinElmer, Inc. announced it had successfully completed its acquisition of Oxford Immunotec Global PLC. Oxford Immunotec was recognized as a global leader in T-cell immunology, with its T-SPOT.TB test being a leading FDA-approved and CE-marked blood test for tuberculosis. The acquisition aimed to expand PerkinElmer's portfolio of infectious disease testing solutions....more
The Wales Cancer Biobank (WCB) via Revvity News • February 23, 2024
The Wales Cancer Biobank (WCB) is utilizing Revvity's T-SPOT Discovery SARS-CoV-2 kit for research into the T cell immune response to COVID-19 infection and vaccination in cancer patients. This technology, based on the T-SPOT platform pioneered by Oxford Immunotec, aids in understanding cellular immunity....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including OXFORD IMMUNOTEC GLOBAL PLC, are just a search away.